Pupils in schools are much more likely to be excluded if they have a history of social care

The FDA has told No­var­tis, Gilead, Bris­tol My­ers Squibb and John­son & John­son to add boxed warn­ings on the la­bels of six CAR-T ther­a­pies not­ing

Researchers have now reported full 52-week results from the two parallel phase III trials of the interleukin-17 (IL-17) blocker bimekizumab in axial spondyloarthritis (axSpA), following